Stable Response to IL-13 and IL-13/4 Inhibitor Treatment in Moderate-to- Severe AD.

0 SAR
Checkout

Overview

In this video, Prof. Jonathan Silverberg discusses the stability and durability of clinical
response with lebrikizumab, an IL-13 inhibitor, compared with IL-13/4 inhibitor
treatment in moderate-to-severe atopic dermatitis. He reviews how targeted IL-13
inhibition supports sustained control of key disease measures, including disease severity
and itch response, supporting maintenance of long-term treatment response in moderate-
to-severe AD.


This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • ● Review the concept of stable, sustained response with lebrikizumab
    in moderate-to-severe atopic dermatitis.
    ● Compare durability of response between IL-13 inhibition and IL-13/4
    inhibitor treatment treatment in moderate-to-severe atopic
    dermatitis.
    ● Summarize the clinical evidence supporting maintenance of response
    over time.
    ● Explain how targeted IL-13 inhibition supports stable, long-term
    treatment response with lebrikizumab in moderate-to-severe atopic
    dermatitis.

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

    PP-LK-SA-0196


Related Classes